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Background
Several studies have shown a high frequency of vitamin D
deficiency among HIV patients. Several studies have
ascribed these low levels of vitamin D to antiretroviral
treatment, especially efavirenz. Tenofovir has been
related to changes of bone mineralization in SIV-infected
rhesus monkeys and with loss of bone mineral density in
children. Adequate vitamin D stores have the potential of
an improvement of immune status, lessening of cardio-
vascular risk and beneficial effects on certain neoplastic
disorders.
Methods
Cross-sectional study of 94 adult HIV outpatients in
Leganés (Madrid, Spain) performed in 2008. Risk factors
for vitamin D deficiency (< 20 µg/L) were examined
using logistic regression.
Results
Median age was 44 years (IQR 40 to 48); 69.1% were
males, 93,6% whites, 6.4% black race. Mean CD4+ cell
count was 446 cells/µL (IQR 312 to 586). Viral load was
below 50 copies/mL in 78.7%. Median 25(OH)D level was
17.7 µg/L (IQR 11.9 TO 24.3). 87.2% of patients had
25(OH)D < 30 µg/L (suboptimal), 57.4% had 25(OH)D
< 20 µg/L (deficient ) and 19.1% < 10 µg/L (severely defi-
cient). Factors associated with low levels of 25(OH)D were
heterosexual vs. IVDU HIV-risk group (OR 13.3, 95% CI
2.4-74.1, p=0.003), season (spring vs. summer; OR 16.8,
95% CI 3.4-82.1, p=0.0001), age >45 vs < 45 years (OR
10.5, 95% CI 2.4-46.6%, p=0.002), CD4+ cells nadir <200
vs >200 cells/µL (OR 4.1, 95% CI 1.01-17.6, p=0.049), and
tenofovir vs. abacavir therapy (OR 12.7, 95% CI 1.8-87.1,
p=0.01). Black race is underrepresented to draw conclu-
sions. In this sample, no association of low 25(OH)D with
efavirenz was found.
Conclusions
Despite low latitude, low levels of vitamin D are almost
universal in our sample of HIV outpatients with satisfac-
tory immunologic and virologic response to ART. Increas-
ing age, less insolation season, heterosexual risk group,
and CD4+ nadir were associated with lower levels. Teno-
fovir use was associated with lower levels of 25(OH)D.
Further studies on causality of this association and the
need of control bone-mineral density in tenofovir-treated
patients seems warranted.
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